The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
You have to love those lse algos & printouts. Everything above 9.3p was a buy with the bid at 9p, but 650k shares bought at 10p, goes through as an unknown trade?!.
Be you a ramper, deramper, in profit or bagholder, the inescapable facts are that, there are no funders, no clients, negligible revenues & 90% of what AZ has been promising has yet to materialise.
I invested £30k in June 20, hoping to triple my investment in 5 years. Reality looks much more like I will have lost it all in 3 years.
Needs £500m in signed contracts in 2023 to avoid the need to try and borrow more money.
Who in their right mind would give this guy more cash.
Thats all well and good, but a 100% conversion rate would only generate £10m of revenue. Lets inject a degree of reality and assume 50% conversion rate. £5m in revenue does not come close to covering annual opex.
Syme need a far larger pipeline than that to survive.
The worrying bit for me is that, every other stock I am invested in has gained between 15 & 40% since Jan 3rd. Contract wins, trading updates, investor presentations etc. You have to question what this lot actually do for 200 hrs a month. Total radio silence.
Take your pick, people holding on to their shares, lack of liquidity, MM's looking to fill ii orders at sub 8p. Potential risk v reward still too high for some investors. Marketing confined to a very small number of outlets and Polb unknown to those not already invested.
Personally think we will be in the 8 to 10p range until the full data is released or any licensing/partnership deals are announced
That question was raised and answered during the presentation.
https://www.thearmchairtrader.com/conviction-life-sciences-pushes-back-ipo-to-end-january/